Okku Park

Title: Okku Park: Innovator in Antibody-Drug Conjugates

Introduction

Okku Park is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of antibody-drug conjugates. With a total of 6 patents, Park's work is recognized for its potential therapeutic applications.

Latest Patents

Among his latest patents, Park has developed substituted benzodiazepines as antibody-drug conjugates. This patent provides compounds and compositions that include substituted benzodiazepines of a specific class. Another significant patent involves antibody-drug conjugates comprising anti-B7-H3 antibodies. This disclosure relates to ADCs where active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker is designed to covalently connect active agents to the antibody. Furthermore, the patent discusses monoclonal antibodies and their variants that specifically bind to B7-H3, along with methods for their therapeutic, diagnostic, and prophylactic use.

Career Highlights

Throughout his career, Okku Park has worked with various companies, including Intocell, Inc. and Y-Biologics Inc. His innovative research has positioned him as a key figure in the development of advanced therapeutic solutions.

Collaborations

Park has collaborated with notable colleagues, including Taekyo Park and Sung Ho Woo. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Okku Park's contributions to the field of antibody-drug conjugates highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic options in the treatment of diseases.